(LABU) Direxion Daily S&P Biotech - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US25460G1206

LABU: Swap Agreements, Securities, ETFs

The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund (ETF) designed to provide investors with 3X daily leveraged exposure to the S&P Biotechnology Select Industry Index, which tracks the biotechnology sub-industry as defined by the Global Industry Classification Standards (GICS).

The fund achieves its investment objective by investing at least 80% of its net assets in a combination of financial instruments, including swap agreements, securities of the index, and ETFs that track the index. As a non-diversified fund, LABU is more susceptible to volatility and potential losses due to its concentrated investment strategy.

From a technical analysis perspective, LABU is currently trading at $48.32, below its 20-day and 50-day simple moving averages (SMA) of $51.60 and $62.76, respectively, indicating a downtrend. The Average True Range (ATR) of 6.40, representing 13.25% of the current price, suggests high volatility. Given the 52-week high and low of $148.47 and $37.64, respectively, the current price is near the lower end of its recent range.

Fundamentally, LABU has $585.93 million in assets under management (AUM), indicating a moderate level of investor interest. The biotechnology sector, which LABU tracks, is known for its potential for high growth due to ongoing innovation and the development of new treatments and therapies. However, it is also characterized by high risk due to the inherent uncertainties associated with drug development and regulatory approvals.

Forecasting LABUs future performance involves analyzing both its technical and fundamental data. Technically, a break above the resistance level of $62.0 could signal a potential uptrend, while a drop below the support level of $30.0 could indicate further declines. Fundamentally, the growth prospects of the biotechnology sector, driven by advancements in medical research and the demand for new treatments, could support LABUs long-term performance. However, the leveraged nature of LABU means that it is more sensitive to market movements, making it more suitable for short-term trading strategies rather than long-term investments.

Given the current technical downtrend and the high volatility of LABU, a cautious approach is warranted. Investors should closely monitor the funds price movements in relation to its support and resistance levels and be prepared to adjust their strategies accordingly. For those looking to capitalize on short-term movements, LABU could offer opportunities, but it is crucial to manage risk through appropriate position sizing and stop-loss orders.

Additional Sources for LABU ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

LABU ETF Overview

Market Cap in USD 586m
Category Trading--Leveraged Equity
TER 0.96%
IPO / Inception 2015-05-28

LABU ETF Ratings

Growth Rating -90.4
Fundamental -
Dividend Rating 1.0
Rel. Strength -50.1
Analysts -
Fair Price Momentum 30.96 USD
Fair Price DCF -

LABU Dividends

Dividend Yield 12m 0.32%
Yield on Cost 5y 0.03%
Annual Growth 5y -14.96%
Payout Consistency 50.1%
Payout Ratio %

LABU Growth Ratios

Growth Correlation 3m -15.7%
Growth Correlation 12m -85.6%
Growth Correlation 5y -87.1%
CAGR 5y -42.39%
CAGR/Max DD 5y -0.43
Sharpe Ratio 12m 0.48
Alpha -76.48
Beta 2.998
Volatility 86.95%
Current Volume 1058.3k
Average Volume 20d 1883.2k
What is the price of LABU shares?
As of June 16, 2025, the stock is trading at USD 58.76 with a total of 1,058,254 shares traded.
Over the past week, the price has changed by -2.73%, over one month by +22.31%, over three months by -26.58% and over the past year by -44.81%.
Is Direxion Daily S&P Biotech a good stock to buy?
No, based on ValueRay´s Analyses, Direxion Daily S&P Biotech (NYSE ARCA:LABU) is currently (June 2025) a stock to sell. It has a ValueRay Growth Rating of -90.36 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LABU is around 30.96 USD . This means that LABU is currently overvalued and has a potential downside of -47.31%.
Is LABU a buy, sell or hold?
Direxion Daily S&P Biotech has no consensus analysts rating.
What are the forecasts for LABU share price target?
According to our own proprietary Forecast Model, LABU Direxion Daily S&P Biotech will be worth about 37.2 in June 2026. The stock is currently trading at 58.76. This means that the stock has a potential downside of -36.76%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 37.2 -36.8%